Cardiovascular hormones, hsTnT and cytokines at different tumour stages
| Variables | Stage 1 (n=96) | Stage 2 (n=50) | Stage 3 (n=108) | Stage 4 (n=183) | p Value tumour stages 1, 2, 3 vs tumour stage 4 |
|---|---|---|---|---|---|
| hsTnT, ng/mL (IQR) | 0.005 (0.003 to 0.009) | 0.004 (0.003 to 0.007) | 0.006 (0.003 to 0.011) | 0.007 (0.004 to 0.012) | <0.001 |
| NT-proBNP, pg/mL (IQR) | 103 (48 to 190) | 105 (58 to 191) | 118 (73 to 257) | 168 (74 to 377) | 0.002 |
| MR-proANP, pmol/L (IQR) | 56.2 (45.3 to 83.8) | 61.1 (51.4 to 71.2) | 59.4 (41.6 to 99.9) | 67.7 (47.4 to 113.5) | 0.016 |
| MR-proADM, nmol/L (IQR) | 0.49 (0.41 to 0.65) | 0.51 (0.44 to 0.63) | 0.53 (0.41 to 0.68) | 0.62 (0.48 to 0.82) | <0.001 |
| CT-proET-1, pmol/L (IQR) | 45.8 (39.0 to 57.4) | 45.8 (38.3 to 58.6) | 48.6 (38.0 to 59.1) | 57.2 (42.4 to 74.1) | <0.001 |
| Copeptin, pmol/L (IQR) | 3.7 (2.5 to 6.9) | 3.5 (2.5 to 5.0) | 3.9 (2.6 to 6.6) | 5.4 (3.2 to 10.6) | <0.001 |
| CRP, mg/L (IQR) | 0 (0 to 1) | 0 (0 to 1) | 0 (0 to 1) | 1 (0 to 2) | <0.001 |
| IL-6, pg/mL (IQR) | 2 (2 to 2) | 2 (2 to 3) | 2 (2 to 3) | 2 (2 to 3) | 0.011 |
| Fibronectin, mg/dL (IQR) | 43 (36 to 47) | 43 (34 to 48) | 43 (36 to 49) | 42 (35 to 49) | 0.504 |
| Haptoglobin, mg/dL (IQR) | 119 (93 to 171) | 144 (108 to 214) | 146 (96 to 214) | 178 (129 to 249) | <0.001 |
| Serum amyloid, µg/mL (IQR) | 7 (4 to 17) | 8 (4 to 25) | 8 (5 to 19) | 17 (6 to 51) | <0.001 |
Variables are displayed as median and IQR. Difference between patients with tumour stages 1, 2, 3 versus patients with tumour stage 4 was calculated by the means of the Mann–Whitney U test.
Fonts in bold indicate statistical significance (p<0.05).
CRP, C reactive protein; CT-proET-1, C-terminal pro endothelin-1; hsTnT, high-sensitive troponin T; IL-6, interleukin 6; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide.